Cargando…

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Detalles Bibliográficos
Autores principales:	Gurnari, Carmelo, Piciocchi, Alfonso, Soddu, Stefano, Bonanni, Fabrizio, Scalzulli, Emilia, Niscola, Pasquale, Di Veroli, Ambra, Piccioni, Anna Lina, Piedimonte, Monica, Maiorana, Gianluca, Salutari, Prassede, Cicconi, Laura, Santopietro, Michelina, Gumenyuk, Svitlana, Sarlo, Chiara, Fenu, Susanna, Tafuri, Agostino, Latagliata, Roberto, Fianchi, Luana, Criscuolo, Marianna, Maciejewski, Jaroslaw P., Maurillo, Luca, Buccisano, Francesco, Breccia, Massimo, Voso, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452671/ https://www.ncbi.nlm.nih.gov/pubmed/36071048 http://dx.doi.org/10.1038/s41408-022-00724-3

Ejemplares similares

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry
por: Mayer, Flavia, et al.
Publicado: (2017)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
por: Guarnera, Luca, et al.
Publicado: (2023)

Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
por: Breccia, Massimo, et al.
Publicado: (2011)

Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
por: Molica, Matteo, et al.
Publicado: (2022)

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
por: Sarlo, Chiara, et al.
Publicado: (2013)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
por: Buccisano, Francesco, et al.
Publicado: (2021)

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
por: Puzzolo, Maria Cristina, et al.
Publicado: (2022)

Clonal evolution in therapy-related neoplasms
por: Fabiani, Emiliano, et al.
Publicado: (2017)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
por: Faraoni, Isabella, et al.
Publicado: (2019)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Therapy-related myeloid neoplasms: clinical perspectives
por: Fianchi, Luana, et al.
Publicado: (2018)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Prognostic factors and treatment of secondary leukemia
por: Voso, Maria Teresa, et al.
Publicado: (2018)

Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis
por: Falconi, Giulia, et al.
Publicado: (2022)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

Similarities and Differences Between Therapy-Related and Elderly Acute Myeloid Leukemia
por: D’Alò, Francesco, et al.
Publicado: (2011)

Management of Acute Promyelocytic Leukemia in the Elderly
por: Lo-Coco, Francesco, et al.
Publicado: (2013)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
por: Molica, Matteo, et al.
Publicado: (2019)

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
por: Falconi, Giulia, et al.
Publicado: (2018)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
por: Fianchi, Luana, et al.
Publicado: (2012)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA
por: Efficace, Fabio, et al.
Publicado: (2023)

Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts
por: Maurillo, Luca, et al.
Publicado: (2013)

Progress and criticalities in the management of acute promyelocytic leukemia
por: Lo-Coco, Francesco, et al.
Publicado: (2017)

Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding
por: Awada, Hassan, et al.
Publicado: (2020)

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience
por: Mossuto, Sandra, et al.
Publicado: (2020)

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma
por: Pasqualone, Gianmario, et al.
Publicado: (2022)

Invasive Candida Infections in Patients With Haematological Malignancies and Hematopoietic Stem Cell Transplant Recipients: Current Epidemiology and Therapeutic Options.
por: Girmenia, Corrado, et al.
Publicado: (2011)

Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Mastocytosis: One Word for Different Diseases
por: Criscuolo, Marianna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_14km667fblqpslt8mpt3bmmebj